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We appreciate the comments made by Dr Yildirim and colleagues. 1 First, we agree that preanalytical factors play a key role in obtaining reliable results and that such errors can result in erroneous conclusions. Thus, all blood samples in our study 2 were tested within 1 hour of collection. Second, we used ethylenediaminetetraacetic acid (EDTA) for whole blood anticoagulation. 2 Some reports demonstrated that the mean platelet volume (MPV) increases with the use of EDTA due to platelet swelling, thus, suggesting the use of acid citrate as anticoagulant. 3 However, most studies indicate that MPV can be measured accurately by both methods of anticoagulation-EDTA and citrate-if analysis is performed within 1 hour of sampling. Dastjerdi et al evaluated whether EDTA-and citrate-based anticoagulated blood samples can be used interchangeably for MPV measurement. 4 In the 61 patients, there was a close correlation between MPV as measured in EDTA and citrate, but MPV measured from EDTA samples was 0.66 fL (9%) greater than when collected in citrate. Both methods also showed a significant negative correlation between platelet count and MPV. The study indicates that MPV can be measured accurately by both methods of anticoagulation, EDTA and citrate, if the analysis is performed within 1 hour of sampling. 4 Lance et al also demonstrated that platelets swell until 120 minutes in EDTA and until 60 minutes in citrate. 5 So they suggest that optimal measuring time should not exceed 120 minutes. Interestingly, they demonstrated that the platelet count was most stable in EDTA. 5 As to plateletcrit, it provides data regarding total platelet mass, whereas MPV and platelet larger cell ratio (P-LCR) are indicators of circulating larger platelets (>12 fL) and have also been used to monitor platelet activity. These are the reasons why we chose to study the associations of MPV and P-LCR with pentraxin 3 (PTX3) and C-reactive protein (CRP). Furthermore, there is paucity of data on the role of plateletcrit in stable coronary artery disease. Therefore, we did not record this variable in our study. Notwithstanding, the authors 2 make an interesting point for future studies.
Regarding correlation between CRP and platelet to lymphocyte ratio (PLR), and lack thereof between PTX3 and PLR, we speculate that different mechanisms underlie this phenomenon. One possibility might be the local nature of PTX3 actions in contrast to the systemic actions of CRP. However, we cannot exclude that our results are limited by a relatively small sample size.
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